Bayer AG - Product Pipeline Review - 2014

Date: May 21, 2014
Pages: 202
Price:
US$ 1,500.00 US$ 1,350.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BB6C9F04A02EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Bayer AG - Product Pipeline Review - 2014’, provides an overview of the Bayer AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bayer AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Bayer AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Bayer AG’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Bayer AG’s pipeline products
Reasons to buy
  • Evaluate Bayer AG’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Bayer AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Bayer AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Bayer AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bayer AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Explore the dormant and discontinued projects of Bayer AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Bayer AG Snapshot
Bayer AG Overview
Key Information
Key Facts
Bayer AG - Research and Development Overview
Key Therapeutic Areas
Bayer AG - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Bayer AG - Pipeline Products Glance
Bayer AG - Late Stage Pipeline Products
Bayer AG - Clinical Stage Pipeline Products
Bayer AG - Early Stage Pipeline Products
Bayer AG - Unknown Stage Pipeline Products
Bayer AG - Drug Profiles (gestodene + ethinyl estradiol)
aflibercept
regorafenib
riociguat
sorafenib tosylate
rivaroxaban (diphenhydramine hydrochloride + naproxen sodium) (nifedipine + candesartan cilexetil)
amikacin
BAY-818781
BAY-818973
BAY-949027
ciprofloxacin
mapracorat
radium Ra 223 dichloride
tedizolid phosphate
BAY-1002670
BAY-1021189
BAY-1067197
BAY-858501
copanlisib
finerenone
molidustat
refametinib
sagopilone
BAY-1000394
Autologous Recombinant Idiotypic Vaccine
BAY-1026153
BAY-1082439
BAY-1125976
BAY-1129980
BAY-1143572
BAY-1163877
BAY-1179470
BAY-868050
BAY-949343
BAY-1001931
BAY-1024767
BAY-606583
Bay-846
BR-4628
BR-5489
HER-2 Payload
Monoclonal Antibodies for Cancer
PDGFR-Beta Payload
Small Molecule to Inhibit Kinase for Cancer
ZK-191784
ZK-216348
Small Molecule to Inhibit Epigenetic Target for Cancer
Thorium-227 Avibody Conjugate
Thorium-Anti CD22 Monoclonal Antibody
Drugs Targeting Tumor Specific Gene Mutations for Cancer
Immunotherapy for Cancer
Bayer AG - Pipeline Analysis
Bayer AG - Pipeline Products by Target
Bayer AG - Pipeline Products by Route of Administration
Bayer AG - Pipeline Products by Molecule Type
Bayer AG - Pipeline Products by Mechanism of Action
Bayer AG - Recent Pipeline Updates
Bayer AG - Dormant Projects
Bayer AG - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Bayer AG - Company Statement
Bayer AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Bayer AG, Key Information
Bayer AG, Key Facts
Bayer AG - Pipeline by Indication, 2014
Bayer AG - Pipeline by Stage of Development, 2014
Bayer AG - Monotherapy Products in Pipeline, 2014
Bayer AG - Combination Treatment Modalities in Pipeline, 2014
Bayer AG - Partnered Products in Pipeline, 2014
Bayer AG - Partnered Products/ Combination Treatment Modalities, 2014
Bayer AG - Out-Licensed Products in Pipeline, 2014
Bayer AG - Out-Licensed Products/ Combination Treatment Modalities, 2014
Bayer AG - Pre-Registration, 2014
Bayer AG - Filing rejected/Withdrawn, 2014
Bayer AG - Phase III, 2014
Bayer AG - Phase II, 2014
Bayer AG - Phase I, 2014
Bayer AG - Preclinical, 2014
Bayer AG - Discovery, 2014
Bayer AG - Unknown, 2014
Bayer AG - Pipeline by Target, 2014
Bayer AG - Pipeline by Route of Administration, 2014
Bayer AG - Pipeline by Molecule Type, 2014
Bayer AG - Pipeline Products by Mechanism of Action, 2014
Bayer AG - Recent Pipeline Updates, 2014
Bayer AG - Dormant Developmental Projects,2014
Bayer AG - Discontinued Pipeline Products, 2014
Bayer AG, Subsidiaries

LIST OF FIGURES

Bayer AG - Pipeline by Top 10 Indication, 2014
Bayer AG - Pipeline by Stage of Development, 2014
Bayer AG - Monotherapy Products in Pipeline, 2014
Bayer AG - Combination Treatment Modalities in Pipeline, 2014
Bayer AG - Partnered Products in Pipeline, 2014
Bayer AG - Out-Licensed Products in Pipeline, 2014
Bayer AG - Pipeline by Top 10 Target, 2014
Bayer AG - Pipeline by Top 10 Route of Administration, 2014
Bayer AG - Pipeline by Top 10 Molecule Type, 2014
Bayer AG - Pipeline Products by Top 10 Mechanism of Action, 2014

Ask Your Question

Bayer AG - Product Pipeline Review - 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: